CELG - Celgene Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
89.63
+1.26 (+1.43%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close88.37
Open87.76
Bid0.00 x 2900
Ask0.00 x 1000
Day's Range87.76 - 89.63
52 Week Range58.59 - 95.30
Volume4,834,621
Avg. Volume11,506,221
Market Cap62.952B
Beta (3Y Monthly)1.84
PE Ratio (TTM)16.27
EPS (TTM)5.51
Earnings DateMay 2, 2019 - May 6, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est97.66
Trade prices are not sourced from all markets
  • Bristol-Myers' Celgene Buyout Still Uncertain Amid Opposition
    Zacks17 hours ago

    Bristol-Myers' Celgene Buyout Still Uncertain Amid Opposition

    The acquisition deal between Bristol-Myers and Celgene faces opposition from stakeholders of Bristol-Myers. The future of the deal depends on the outcome of the Special Meeting in April.

  • Barrons.com20 hours ago

    Proxy Advisors Could Tilt the Scales in the Bristol-Celgene Deal. Watch for Their Calls Next Week.

    Management and shareholders at Bristol-Myers Squibb continue to spar over the firm’s proposed acquisition of Celgene. Recommendations from proxy-advisory firms will be critical to whether the deal goes ahead.

  • Amid Bristol-Starboard Duel Over Celgene, Here's What's Really Key
    Investor's Business Dailyyesterday

    Amid Bristol-Starboard Duel Over Celgene, Here's What's Really Key

    Bristol-Myers Squibb and activist shareholder Starboard Value are still tussling over the looming $74 billion Celgene acquisition, but analysts are looking ahead to a key proxy vote.

  • Emergent Begins Phase III Study on Anthrax Vaccine AV7909
    Zacks2 days ago

    Emergent Begins Phase III Study on Anthrax Vaccine AV7909

    Emergent (EBS) kicks off a late-stage study on its investigational anthrax vaccine AV7909.

  • Buy These 5 ROE Stocks as Stock Market Euphoria Continues
    Zacks2 days ago

    Buy These 5 ROE Stocks as Stock Market Euphoria Continues

    ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.

  • The Zacks Analyst Blog Highlights: Hilton, Xilinx, Quanta, Anthem and Celgene
    Zacks2 days ago

    The Zacks Analyst Blog Highlights: Hilton, Xilinx, Quanta, Anthem and Celgene

    The Zacks Analyst Blog Highlights: Hilton, Xilinx, Quanta, Anthem and Celgene

  • Starboard vs. Bristol-Myers Squibb: Who'll Win This Brewing Battle?
    Motley Fool2 days ago

    Starboard vs. Bristol-Myers Squibb: Who'll Win This Brewing Battle?

    An activist investor made a strong argument for walking away from Celgene, but will investors listen?

  • The Wall Street Journal2 days ago

    [$$] If This Is Failure, Show Me Success

    In a nearly 200-page presentation calling for investors to reject Bristol-Myers Squibb’s proposed acquisition of Celgene released on Monday, activist hedge fund Starboard Value called Celgene’s pipeline of new drugs “unproven.

  • Puma Biotech's (PBYI) Nerlynx Gets Approval in Australia
    Zacks2 days ago

    Puma Biotech's (PBYI) Nerlynx Gets Approval in Australia

    Puma Biotech (PBYI) gains an approval in Australia for Nerlynx as an extended adjuvant treatment in adult patients with early stage HER2-positive breast cancer.

  • Analysts Have Revised BMY’s Target Price Downward in March
    Market Realist2 days ago

    Analysts Have Revised BMY’s Target Price Downward in March

    How Major Pharmaceutical Stocks Are Positioned This Month(Continued from Prior Part)Analysts’ recommendations and target priceAnalysts expect an upside potential of 13.72% for Bristol-Myers Squibb (BMY) based on the company’s closing price on

  • Catalyst (CPRX) Reports Wider Q4 Loss, Focuses on Firdapse
    Zacks3 days ago

    Catalyst (CPRX) Reports Wider Q4 Loss, Focuses on Firdapse

    Catalyst (CPRX) reports wider-than-expected loss in the fourth quarter of 2018.

  • Barrons.com3 days ago

    Starboard Is Against the Bristol-Myers and Celgene Deal. Now It Gets Interesting.

    Less than a month before shareholders vote on Bristol-Myers Squibb’s proposed take over of Celgene, activist hedge fund Starboard Value released a presentation detailing its opposition to the deal.

  • TheStreet.com3 days ago

    Bristol-Myers Pushes Celgene Deal, Starboard Hits Back, in $74B Takeover Spat

    traded blows with activist investor Starboard Value LP Tuesday as the pair issued competing presentations linked to the pharmaceutical group's planned $74 billion takeover of cancer drug specialist Celgene Corp. Bristol Myers said the deal, which if first unveiled in early January, would mean give combined companies number one positions in oncology and cardiovascular drug sales, with a top five standing in immunology and inflammation and nine currency products with over $1 billion in sales. Starboard, for its part, opposes the deal, arguing Celgene is a company facing a "massive patent cliff" that will force it to replace some 60% of its revenues over the next seven years.

  • PhaseBio Stock Up on Positive Data From PB2452 Phase I Study
    Zacks3 days ago

    PhaseBio Stock Up on Positive Data From PB2452 Phase I Study

    PhaseBio's (PHAS) stock skyrockets on positive data from an early-stage study evaluating PB2452, showing immediate and sustained reduction in bleeding risk in patients taking AstraZeneca's Brilinta.

  • Allergan's Anti-Infective Gets FDA Nod for Pediatric Patients
    Zacks3 days ago

    Allergan's Anti-Infective Gets FDA Nod for Pediatric Patients

    The FDA approves Allergan's (AGN) sNDA for the label expansion of its antibacterial medicine, Avycaz, to treat cUTI and cIAI in pediatric patients.

  • TheStreet.com3 days ago

    Why Shareholders Should Vote for Bristol-Myers Celgene Deal: Jim Cramer

    Jim Cramer thinks that Bristol-Myer's deal with Celgene is a positive thing, despite Starboard's resistance.

  • TheStreet.com3 days ago

    Jim Cramer: Tilray's Earnings, Bristol-Myers and Celgene and Elon Musk

    Bristol-Myers, Tilray, and Elon Musk are some of the top headlines in business news Tuesday. Here's what Jim Cramer's watching.

  • TheStreet.com3 days ago

    Jim Cramer Breaks Down Tilray Earnings, Elon Musk's Twitter and Bristol-Myers

    posted a wider-than-expected fourth quarter loss but said sales nearly tripled in a growing global market for medical marijuana. Tilray said earnings for the three months ending in December were pegged at a net loss of 33 cents per share, compared to a 4 cents per share profit from the same period in 2017, a figure it put down to "operating expenses related to growth initiatives, expansion of international teams and costs related to financings and M&A activities." Group sales, however, rose more than 200% to $15.5 million, while total kilogram equivalents increased nearly three-fold to 2,053 and the average net selling price rose 5.5% to $7.52 per gram, reported TheStreet's Martin Baccardax. Elon Musk is still in hot water with the SEC about his Twitter presence.

  • Are Americans More Confident in 2019? 5 Top Picks
    Zacks3 days ago

    Are Americans More Confident in 2019? 5 Top Picks

    U.S. consumers' net worth took a hit in 2018 owing to a stock market meltdown and tepid housing market conditions.

  • Markit3 days ago

    See what the IHS Markit Score report has to say about Celgene Corp.

    Celgene Corp NASDAQ/NGS:CELGView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is extremely low for CELG with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting CELG. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding CELG are favorable, with net inflows of $11.87 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Bristol-Myers Squibb and Starboard Value square off over Celgene deal
    American City Business Journals3 days ago

    Bristol-Myers Squibb and Starboard Value square off over Celgene deal

    Activist investor says Bristol-Myers' Celgene deal "is ill-advised and could destroy substantial value for shareholders"; Bristol-Myers argues the deal "is a financially and strategically compelling transaction."

  • Bristol-Myers & Pfizer Release Phase IV Data on Eliquis
    Zacks3 days ago

    Bristol-Myers & Pfizer Release Phase IV Data on Eliquis

    Bristol-Myers (BMY) and partner Pfizer ) announce results from the phase IV - AUGUSTUS study evaluating Eliquis (apixaban) versus vitamin K antagonists (VKAs).

  • Celgene (CELG) Stock Sinks As Market Gains: What You Should Know
    Zacks3 days ago

    Celgene (CELG) Stock Sinks As Market Gains: What You Should Know

    Celgene (CELG) closed at $87.91 in the latest trading session, marking a -0.62% move from the prior day.

  • Is Celgene (CELG) Outperforming Other Medical Stocks This Year?
    Zacks4 days ago

    Is Celgene (CELG) Outperforming Other Medical Stocks This Year?

    Is (CELG) Outperforming Other Medical Stocks This Year?

  • AstraZeneca Up This Year on New Drugs & Pipeline Progress
    Zacks4 days ago

    AstraZeneca Up This Year on New Drugs & Pipeline Progress

    AstraZeneca's (AZN) stock is on an upward trajectory this year. Let us have a look at the reasons for the same.